RE:Help my MathHey 10-4. Here is what Seeking Alpha thinks about our valuation. Bioniche (Telesta's) $25 million market cap is exceptionally low for a Phase III biotech company. How low? Here's an overview of peer Phase III small cap biotechs targeting specific cancer types with respectively their market valuations: Oncothyreon (NASDAQ:ONTY): $150 million valuation Endocyte (NASDAQ:ECYT): $280 million valuation Galena Biopharma (NASDAQ:GALE): $280 valuation Mind you that most Phase III biotech stocks have much higher valuations (some in the billions), but I searched in the lowest bracket of valuations, and for companies targeting specific cancer types, so their addressable markets are more or less of similar size. A remarkable thing is that some companies failed their Phase III trials so far (OncoGenex for example), but still are valued at multiples of Telesta. Other have weak financials, and are also valued much higher. So even in the lowest bracket of Phase III biotechs, valuations turn out to be 3X to 10X higher than Telesta's, emphasizing clearly what a phenomenal buying opportunity Telesta is. beech